Idiopathic Pulmonary Fibrosis News and Research RSS Feed - Idiopathic Pulmonary Fibrosis News and Research

Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Wresting back control of CHI3L1 protein could stave off cancer spread in mice

Wresting back control of CHI3L1 protein could stave off cancer spread in mice

For cancer to spread, the cells that take off into the bloodstream must find a tissue that will permit them to thrive. They don't just go looking, though. Instead, they actively prepare the tissue, in one case by co-opting a protein that suppresses defenses the body would otherwise mount. [More]
Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF). [More]
3-D imaging of fibroblastic foci may help researchers study disease progression in IPF patients

3-D imaging of fibroblastic foci may help researchers study disease progression in IPF patients

Idiopathic pulmonary fibrosis (IPF) is a fatal disease in which progressive scarring of the lungs leads to respiratory failure. Lung scarring in IPF takes the form of aggregates of proliferating fibroblasts and myofibroblasts, known as "fibroblastic foci", which deposit collagen and other fibrotic components. These foci are thought to form in response to lung injury. [More]
M10 peptide could help protect systemic sclerosis patients against fibrotic damage

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

The results of preclinical studies by investigators at the Medical University of South Carolina (MUSC) reported in the April 2016 issue of Translational Research suggest that the M10 peptide could help protect against fibrotic damage in patients with systemic sclerosis, particularly in those who develop interstitial lung diseases (ILD), its deadliest complication. [More]
Understanding idiopathic pulmonary fibrosis: an interview with Michael Durheim, M.D.

Understanding idiopathic pulmonary fibrosis: an interview with Michael Durheim, M.D.

IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65. [More]
VolitionRx's NuQ blood test accurately detects 86% of subjects with Idiopathic Pulmonary Fibrosis

VolitionRx's NuQ blood test accurately detects 86% of subjects with Idiopathic Pulmonary Fibrosis

VolitionRx Limited today announced preliminary data from a pilot study demonstrating that the Company’s NuQ® blood test detected 86% of subjects with a deadly lung disease, called Idiopathic Pulmonary Fibrosis (IPF). [More]
Systemic sclerosis: an interview with Dr Kristin Highland

Systemic sclerosis: an interview with Dr Kristin Highland

Systemic sclerosis, also known as scleroderma, is a rare disease characterized by the thickening and scarring of connective tissue of multiple organs in the body [More]
New international survey provides insights into emotional truths of living with IPF

New international survey provides insights into emotional truths of living with IPF

An international survey of over 500 people living with idiopathic pulmonary fibrosis (IPF) in more than 20 countries worldwide reveals the real-life emotions faced by those with the devastating disease. [More]
Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB Investment, and Epidarex Capital. [More]
DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF). [More]
Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Boehringer Ingelheim announced today that the first person has been enrolled in the SENSCIS (Safety and Efficacy ofNintedanib in Systemic SClerosIS) study. [More]
IPF-PRO Registry data sheds light on characteristics of people with idiopathic pulmonary fibrosis

IPF-PRO Registry data sheds light on characteristics of people with idiopathic pulmonary fibrosis

Boehringer Ingelheim Pharmaceutical, Inc. today announced initial results of the first 49 people enrolled in the IPF-PRO Registry, which shed light on characteristics of people with IPF at the time of diagnosis. [More]
Boehringer Ingelheim, BioMed X apply crowdsourcing approach to establish research team for identifying COPD treatment

Boehringer Ingelheim, BioMed X apply crowdsourcing approach to establish research team for identifying COPD treatment

Boehringer Ingelheim and BioMed X announced today that they have successfully applied a crowdsourcing approach to establish a research team of outstanding scientists from around the world with bright ideas, who will endeavor to identify new approaches for the treatment of patients with chronic obstructive pulmonary disease (COPD). [More]
Ex-vivo lung perfusion technique can reduce risk of transplant rejection

Ex-vivo lung perfusion technique can reduce risk of transplant rejection

University of Manchester researchers have used a new technique to recondition poorly functioning lungs and remove donor white blood cells in an attempt to increase the number of lungs available for transplant, and at the same time reduce the risk of acute rejection. [More]
Simple stem cell production method shows promise in mice for treating IPF

Simple stem cell production method shows promise in mice for treating IPF

In a small pilot study, researchers from North Carolina State University have demonstrated a rapid, simple way to generate large numbers of lung stem cells for use in disease treatment. This method of harvesting and growing a patient's own lung stem cells shows promise in mice for treating idiopathic pulmonary fibrosis (IPF), and could one day provide human IPF sufferers with an effective, less invasive method of treatment for their disease. [More]
PFF, Veracyte partner on U.S. survey exploring patients' diagnostic experiences with interstitial lung diseases

PFF, Veracyte partner on U.S. survey exploring patients' diagnostic experiences with interstitial lung diseases

The Pulmonary Fibrosis Foundation and Veracyte, Inc. announced that the organizations are partnering on a U.S. patient survey to advance understanding of patients' diagnostic experiences with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF). [More]
Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF). [More]
Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a very aggressive form of pulmonary fibrosis and has a particularly poor prognosis. This fatal disease, for which so far no causal therapies exist, is characterized by a massive deposition of connective and scar tissue in the lung, which leads to a progressive loss of lung function and ultimately death. [More]

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines on the treatment of idiopathic pulmonary fibrosis (IPF) have been released by an international group of leading respiratory societies, The new guidelines, issued by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association, were published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States. [More]
Advertisement